PTIX — Protagenic Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.68m
- -$0.15m
Annual income statement for Protagenic Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2.55 | 4.14 | 3.56 | 4.53 | 5.62 |
| Operating Profit | -2.55 | -4.14 | -3.56 | -4.53 | -5.62 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.55 | -4.52 | -3.56 | -5 | -5.53 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.55 | -4.52 | -3.56 | -5 | -5.53 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.55 | -4.52 | -3.56 | -5 | -5.53 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.55 | -4.52 | -3.56 | -5 | -5.53 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.986 | -1.23 | -0.823 | -1.15 | -1.14 |